Biogen BIIB

NAS: BIIB | ISIN: US09062X1037   13/06/2025
130,65 USD (-1,25%)
(-1,25%)   13/06/2025
Grafiek Biogen Inc. Grafiek Biogen Inc.

Biogen Inc. in het nieuws

12 juni 2025 · Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity · Persbericht

27 mei 2025 · Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies · Persbericht

16 april 2025 · Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union · Persbericht

2 april 2025 · Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease · Persbericht

24 maart 2025 · Biogen Announces Plans for New Global Headquarters and Innovation Hub in Kendall Square · Persbericht

11 maart 2025 · Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients · Persbericht

18 februari 2025 · Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments · Persbericht

31 januari 2025 · Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union · Persbericht

27 januari 2025 · FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease · Persbericht

23 januari 2025 · FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA · Persbericht

Profiel Biogen Inc.

Biotechnologie
Gezondheidstechnologie
Productie
Productie van biologische producten

Website: www.biogen.com

Hoofdzetel: Cambridge, Massachusetts vlag Verenigde Staten

Mijn selecties